Understanding and Managing Corticosteroid-Induced Osteoporosis

References

• Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–787. doi:10.1007/s001980200108
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Lix LM, Morin SN, Yogendran M, Metge CJ, Leslie WD. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol. 2013;40(10):1736–1741. doi:10.3899/jrheum.130041
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893–899. doi:10.1359/JBMR.040134
   PubMed Web of Science ®Google Scholar
• Overman RA, Yeh J, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294–298. doi:10.1002/acr.21796
   PubMed Web of Science ®Google Scholar
• Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019;30(6):1145–1156. doi:10.1007/s00198-019-04906-x
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000. doi:10.1359/jbmr.2000.15.6.993
   PubMed Web of Science ®Google Scholar
• Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am. 1998;27(2):465–483. doi:10.1016/S0889-8529(05)70017-7
   PubMed Web of Science ®Google Scholar
• Amiche MA, Albaum JM, Tadrous M, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016;27(5):1709–1718. doi:10.1007/s00198-015-3455-9
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology. 2000;39(12):1383–1389. doi:10.1093/rheumatology/39.12.1383
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Morin SN, Lix LM, Leslie WD. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study. Osteoporos Int. 2013;24(9):2493–2498. doi:10.1007/s00198-013-2352-3
   Web of Science ®Google Scholar
• De Vries F, Bracke M, Leufkens HGM, Lammers JWJ, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208–214. doi:10.1002/art.22294
   PubMed Web of Science ®Google Scholar
• Wang L, Heckmann BL, Yang X, Long H. Osteoblast autophagy in glucocorticoid-induced osteoporosis. J Cell Physiol. 2019;234(4):3207–3215. doi:10.1002/jcp.27335
   PubMed Web of Science ®Google Scholar
• Hayashi K, Yamaguchi T, Yano S, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009;379(2):261–266. doi:10.1016/j.bbrc.2008.12.035
   Web of Science ®Google Scholar
• Song L, Liu M, Ono N, Bringhurst FR, Kronenberg HM, Guo J. Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J Bone Miner Res. 2012;27(11):2344–2358. doi:10.1002/jbmr.1694
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone. 2010;46(3):564–570. doi:10.1016/j.bone.2009.06.030
   PubMed Web of Science ®Google Scholar
• Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6(10):e25900. doi:10.1371/journal.pone.0025900
   PubMed Web of Science ®Google Scholar
• Jia D, O’brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006;147(12):5592–5599. doi:10.1210/en.2006-0459
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Glucocorticoids and the osteoclast. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S37–S39.
   PubMed Web of Science ®Google Scholar
• Kim H-J. New understanding of glucocorticoid action in bone cells. BMB Rep. 2010;43(8):524–529. doi:10.5483/BMBRep.2010.43.8.524
   PubMed Web of Science ®Google Scholar
• Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone. 2001;29(6):498–505. doi:10.1016/S8756-3282(01)00610-X
   Web of Science ®Google Scholar
• Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest. 1989;83(1):60–65. doi:10.1172/JCI113885
   Web of Science ®Google Scholar
• Delany AM, Durant D, Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol. 2001;15(10):1781–1789. doi:10.1210/mend.15.10.0704
   Google Scholar
• Sato AY, Richardson D, Cregor M, et al. Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology. 2017;158(3):664–677. doi:10.1210/en.2016-1779
   PubMed Web of Science ®Google Scholar
• Ahmad M, Hachemi Y, Paxian K, Mengele F, Koenen M, Tuckermann J. A Jack of all trades: impact of glucocorticoids on cellular cross-talk in osteoimmunology. Front Immunol. 2019;10:2460. doi:10.3389/fimmu.2019.02460
   Web of Science ®Google Scholar
• Paggiosi MA, Peel NFA, Eastell R. The impact of glucocorticoid therapy on trabecular bone score in older women. Osteoporos Int. 2015;26(6):1773–1780. doi:10.1007/s00198-015-3078-1
   Web of Science ®Google Scholar
• Leib ES, Winzenrieth R. Bone status in glucocorticoid-treated men and women. Osteoporos Int. 2016;27(1):39–48. doi:10.1007/s00198-015-3211-1
   Web of Science ®Google Scholar
• Florez H, Hernández-Rodríguez J, Muxi A, et al. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology. 2020;59(7):1574–1580. doi:10.1093/rheumatology/kez464
   PubMed Web of Science ®Google Scholar
• Sandru F, Carsote M, Dumitrascu MC, Albu SE, Valea A. Glucocorticoids and trabecular bone score. J Med Life. 2020;13(4):449–453. doi:10.25122/jml-2019-0131
   Google Scholar
• Saag KG, Agnusdei D, Hans D, et al. Trabecular bone score in patients with chronic glucocorticoid therapy–induced osteoporosis treated with alendronate or teriparatide. Arthritis Rheumatol. 2016;68(9):2122–2128. doi:10.1002/art.39726
   PubMed Web of Science ®Google Scholar
• Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitom. 2004;7(4):359–363. doi:10.1385/JCD:7:4:359
   Web of Science ®Google Scholar
• Kalpakcioglu BB, Engelke K, Genant HK. Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone. 2011;48(6):1221–1231. doi:10.1016/j.bone.2011.02.005
   Web of Science ®Google Scholar
• Lian K-C, Lang TF, Keyak JH, et al. Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naïve postmenopausal women. Osteoporos Int. 2005;16(6):642–650. doi:10.1007/s00198-004-1736-9
   Web of Science ®Google Scholar
• Li EK, Zhu TY, Tam L-S, et al. Bone microarchitecture assessment by high-resolution peripheral quantitative computed tomography in patients with systemic lupus erythematosus taking corticosteroids. J Rheumatol. 2010;37(7):1473LP–1479. doi:10.3899/jrheum.091231
   Web of Science ®Google Scholar
• Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20(3):464–470. doi:10.1359/JBMR.041125
   PubMed Web of Science ®Google Scholar
• Chiodini I, Merlotti D, Falchetti A, Gennari L. Treatment options for glucocorticoid-induced osteoporosis. Expert Opin Pharmacother. 2020;21(6):721–732. doi:10.1080/14656566.2020.1721467
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397. doi:10.1007/s00198-007-0543-5
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–816. doi:10.1007/s00198-010-1524-7
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537. doi:10.1002/art.40137
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257–2276. doi:10.1007/s00198-012-1958-1
   PubMed Web of Science ®Google Scholar
• Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253–259. doi:10.1016/j.bone.2006.02.005
   PubMed Web of Science ®Google Scholar
• Starup-Linde J, Vestergaard P. MANAGEMENT OF ENDOCRINE DISEASE: diabetes and osteoporosis: cause for concern? Eur J Endocrinol. 2015;173(3):R93–R99. doi:10.1530/EJE-15-0155
   PubMed Web of Science ®Google Scholar
• Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis–a comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993;328(24):1747–1752. doi:10.1056/NEJM199306173282404
   Web of Science ®Google Scholar
• Amin S, LaValley MP, Simms RW, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta- analytic approach. Arthritis Rheum. 1999;42(8):1740–1751. doi:10.1002/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol. 1996;23(6):995–1000.
   PubMed Web of Science ®Google Scholar
• Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;125(12):961–968. doi:10.7326/0003-4819-125-12-199612150-00004
   PubMed Web of Science ®Google Scholar
• De Nijs RNJ, Jacobs JWG, Algra A, Lems WF, Bijlsma JWJ. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D 3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004;15(8):589–602. doi:10.1007/s00198-004-1614-5
   PubMed Web of Science ®Google Scholar
• de Nijs RNJ, Jacobs JWG, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355(7):675–684. doi:10.1056/NEJMoa053569
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Chen J-R, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109(8):1041–1048. doi:10.1172/JCI14538
   PubMed Web of Science ®Google Scholar
• Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337(6):382–388. doi:10.1056/NEJM199708073370603
   PubMed Web of Science ®Google Scholar
• Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve- month, multicenter, randomized, double-blind, placebo-controlled, parallel- group study. Arthritis Rheum. 1999;42(11):2309–2318. doi:10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339(5):292–299. doi:10.1056/NEJM199807303390502
   PubMed Web of Science ®Google Scholar
• Allen CS, Yeung JHS, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10. doi:10.1002/14651858.CD001347.pub2
   Web of Science ®Google Scholar
• Siris ES, Fan C-PS, Yang X, Sajjan S, Sen SS, Modi A. Association between gastrointestinal events and compliance with osteoporosis therapy. Bone Rep. 2015;4:5–10. doi:10.1016/j.bonr.2015.10.006
   Google Scholar
• Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253–1263. doi:10.1016/S0140-6736(09)60250-6
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728–1737. doi:10.1056/NEJMoa1010650
   PubMed Web of Science ®Google Scholar
• Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010;69(5):872–875. doi:10.1136/ard.2009.112920
   PubMed Web of Science ®Google Scholar
• Ishiguro S, Ito K, Nakagawa S, Hataji O, Sudo A. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos. 2017;12(1):44. doi:10.1007/s11657-017-0336-1
   Web of Science ®Google Scholar
• Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015;75:222–228. doi:10.1016/j.bone.2015.03.002
   PubMed Web of Science ®Google Scholar
• Iseri K, Iyoda M, Watanabe M, et al. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLoS One. 2018;13(3):e0193846–e0193846. doi:10.1371/journal.pone.0193846
   Web of Science ®Google Scholar
• Saag KG, Pannacciulli N, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four–month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019;71(7):1174–1184. doi:10.1002/art.40874
   Web of Science ®Google Scholar
• Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:2843. doi:10.2147/DDDT.S148654
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Paschou SA, Mintziori G, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23–30. doi:10.1016/j.maturitas.2017.04.008
   PubMed Web of Science ®Google Scholar
• Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–17. doi:10.1016/j.bone.2017.08.003
   PubMed Web of Science ®Google Scholar
• Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone*. Endocr Rev. 1993;14(6):690–709. doi:10.1210/edrv-14-6-690
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi:10.1056/NEJM200105103441904
   PubMed Web of Science ®Google Scholar
• Devogelaer JP, Adler RA, Recknor C, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol. 2010;37(1):141–148. doi:10.3899/jrheum.090411
   PubMed Web of Science ®Google Scholar
• Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid- induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355–1368. doi:10.1002/jbmr.1870
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest. 1998;102(8):1627–1633. doi:10.1172/JCI3914
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–3355. doi:10.1002/art.24879
   PubMed Web of Science ®Google Scholar
• Lespessailles E, Chapurlat R. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. Osteoporos Int. 2020;31(10):1829–1834. doi:10.1007/s00198-020-05568-w
   Web of Science ®Google Scholar
• Kobza AO, Papaioannou A, Lau AN, Adachi JD. Romosozumab in the treatment of osteoporosis. Immunotherapy. 2020;12(13):965–981. doi:10.2217/imt-2020-0158
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–1543. doi:10.1056/NEJMoa1607948
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427. doi:10.1056/NEJMoa1708322
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, Phase 3 trial. Lancet (London, England). 2017;390(10102):1585–1594. doi:10.1016/S0140-6736(17)31613-6
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Blicharski T, Goemaere S, et al. A Phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–3193. doi:10.1210/jc.2017-02163
   PubMed Web of Science ®Google Scholar
• Yao W, Dai W, Jiang L, et al. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int. 2016;27(1):283–294. doi:10.1007/s00198-015-3308-6
   PubMed Web of Science ®Google Scholar
• NIH U.S. National Library of Medicine. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=Osteoporosis&term=romosozumab&cntry=&state=&city=&dist=. Accessed March 21, 2020.
   Google Scholar
• Syed MI, Patel NA, Jan S, Shaikh A, Grunden B, Morar K. Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis. Am J Neuroradiol. 2006;27(9):1938 LP- 1943.
   Web of Science ®Google Scholar
• Amiche MA, Albaum JM, Tadrous M, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. Osteoporos Int. 2016;27(6):1989–1998. doi:10.1007/s00198-015-3476-4
   Web of Science ®Google Scholar
• Ding L, Hu J, Wang D, et al. Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures: network meta-analysis. J Clin Endocrinol Metab. 2020;105(3):600–613. doi:10.1210/clinem/dgz023
   Web of Science ®Google Scholar
• Ward LM. Glucocorticoid-induced osteoporosis: why kids are different. Front Endocrinol (Lausanne). 2020;11:576. doi:10.3389/fendo.2020.00576
   Web of Science ®Google Scholar
• Albaum JM, Lévesque LE, Gershon AS, Liu G, Cadarette SM. Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996–2012. Osteoporos Int. 2015;26(12):2845–2852. doi:10.1007/s00198-015-3200-4
   Web of Science ®Google Scholar
• Buckley LM, Marquez M, Feezor R, Ruffin DM, Benson LL. Prevention of corticosteroid-induced osteoporosis: results of a patient survey. Arthritis Rheum. 1999;42(8):1736–1739. doi:10.1002/1529-0131(199908)42:8<1736::AID-ANR24>3.0.CO;2-E
   Web of Science ®Google Scholar
• Koller G, Katz S, Charrois TL, Ye C. Glucocorticoid-induced osteoporosis preventive care in rheumatology patients. Arch Osteoporos. 2019;14(1):16. doi:10.1007/s11657-019-0570-9
   PubMed Web of Science ®Google Scholar
• Duyvendak M, Naunton M, Van Roon EN, Bruyn GAW, Brouwers JRBJ. Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines. Osteoporos Int. 2008;19(10):1379–1394. doi:10.1007/s00198-008-0598-y
   Web of Science ®Google Scholar
• Guzman-Clark JRS, Fang MA, Sehl ME, Traylor L, Hahn TJ. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2007;57(1):140–146. doi:10.1002/art.22462
   Web of Science ®Google Scholar